CRON vs. TLRY, USNA, CGC, MNMD, BTMD, ACB, CDXC, MDWD, FTLF, and BGXX
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Tilray (TLRY), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
In the previous week, Tilray had 5 more articles in the media than Cronos Group. MarketBeat recorded 9 mentions for Tilray and 4 mentions for Cronos Group. Tilray's average media sentiment score of 1.09 beat Cronos Group's score of 0.43 indicating that Cronos Group is being referred to more favorably in the news media.
Tilray presently has a consensus target price of $2.71, indicating a potential upside of 53.88%. Cronos Group has a consensus target price of $3.00, indicating a potential upside of 21.46%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Tilray is more favorable than Cronos Group.
Tilray has a net margin of -43.98% compared to Tilray's net margin of -61.31%. Cronos Group's return on equity of -2.68% beat Tilray's return on equity.
9.4% of Tilray shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 0.7% of Tilray shares are owned by insiders. Comparatively, 6.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Tilray has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Cronos Group has lower revenue, but higher earnings than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.
Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Summary
Tilray beats Cronos Group on 11 of the 18 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
